New 'Living Drug' trial offers hope for tough blood cancers
NCT ID NCT07200479
Summary
This early-stage study is testing a new type of CAR-T cell therapy called CT1194D in adults whose B-cell blood cancers have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the treatment can shrink or eliminate the cancer. Researchers will also track how long the modified immune cells last and work in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.